Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationship of Hepatocellular Carcinoma Stage and Hepatic Function to Health-Related Quality of Life: A Single Center Analysis.
Gupta A, Zorzi J, Ho WJ, Baretti M, Azad NS, Griffith P, Dao D, Kim A, Philosophe B, Georgiades C, Kamel I, Burkhart R, Liddell R, Hong K, Shubert C, Lafaro K, Meyer J, Anders R, Burns W 3rd, Yarchoan M. Gupta A, et al. Among authors: yarchoan m. Healthcare (Basel). 2023 Sep 18;11(18):2571. doi: 10.3390/healthcare11182571. Healthcare (Basel). 2023. PMID: 37761768 Free PMC article.
BRAF mutation and thyroid cancer recurrence.
Yarchoan M, LiVolsi VA, Brose MS. Yarchoan M, et al. J Clin Oncol. 2015 Jan 1;33(1):7-8. doi: 10.1200/JCO.2014.59.3657. Epub 2014 Nov 24. J Clin Oncol. 2015. PMID: 25422487 No abstract available.
Reply to C. Bal et al and M. Xing.
Yarchoan M, LiVolsi VA, Brose MS. Yarchoan M, et al. J Clin Oncol. 2015 Aug 1;33(22):2483. doi: 10.1200/JCO.2015.61.4859. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124481 No abstract available.
Targeting neoantigens to augment antitumour immunity.
Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Yarchoan M, et al. Nat Rev Cancer. 2017 Aug 24;17(9):569. doi: 10.1038/nrc.2017.74. Nat Rev Cancer. 2017. PMID: 28835723 No abstract available.
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS. Shroff RT, et al. Among authors: yarchoan m. Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25. Br J Cancer. 2017. PMID: 28441383 Free PMC article.
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, Pawlik TM, Kim AK, Zhu Q, Jaffee EM, Taube JM, Anders RA. Yarchoan M, et al. Clin Cancer Res. 2017 Dec 1;23(23):7333-7339. doi: 10.1158/1078-0432.CCR-17-0950. Epub 2017 Sep 19. Clin Cancer Res. 2017. PMID: 28928158 Free PMC article.
105 results